Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05492851 · ClinicalTrials.gov registry record · Phase 4
Trial Comparing Three Single Dose Injections for Knee Osteoarthritis
A Phase 4 study, sponsored by Ohio State University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT05492851 is a Phase 4 study that was terminated before completion, run by Ohio State University. The registered enrollment target is 6 participants.
The verdict
NCT05492851, a Phase 4 study, was terminated before completion, sponsored by Ohio State University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study is a 3-arm, double-blind, randomized trial comparing the clinical outcomes of Zilretta, Synvisc One, and Monovisc for knee OA.
Interventions
- DRUG Zilretta
- DRUG Synvisc-One 48 MG in 6 ML Prefilled Syringe
- DRUG Monovisc 88 MG Per 4 ML Prefilled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2023-01-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05492851
The ClinicalTrials.gov registry entry for NCT05492851 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zilretta is the first listed.
NCT05492851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05492851 about?
NCT05492851 is a clinical study titled "Trial Comparing Three Single Dose Injections for Knee Osteoarthritis". This study is a 3-arm, double-blind, randomized trial comparing the clinical outcomes of Zilretta, Synvisc One, and Monovisc for knee OA.
What is the current status of trial NCT05492851?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2022-08-02. Estimated completion is 2023-01-11.
What interventions are being tested in trial NCT05492851?
The interventions under investigation include: Zilretta (DRUG), Synvisc-One 48 MG in 6 ML Prefilled Syringe (DRUG), Monovisc 88 MG Per 4 ML Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT05492851?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.